Menu Search
Equities

Microbix Biosystems Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MBXBF:QXE

Microbix Biosystems Inc

Actions
  • Price (USD)0.1584
  • Today's Change0.00 / 0.00%
  • Shares traded42.00k
  • 1 Year change-53.42%
  • Beta0.3805
Data delayed at least 15 minutes, as of Jan 30 2026 20:23 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Microbix Biosystems Inc. is a Canada-based company. The Company develops and commercializes proprietary biological and technology solutions for human health and wellbeing. It manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The Company operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.

  • Revenue in CAD (TTM)18.59m
  • Net income in CAD-2.25m
  • Incorporated1978
  • Employees69.00
  • Location
    Microbix Biosystems Inc265 Watline AvenueMISSISSAUGA L4Z 1P3CanadaCAN
  • Phone+1 (905) 361-8910
  • Fax+1 (905) 361-8910
  • Websitehttps://microbix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.